Lance Armstrong and Endurance Medications: How a Regular Patient Gets Access

What Drugs Is Lance Armstrong Associated With?

Armstrong publicly confirmed using EPO, testosterone, human growth hormone, cortisone, and blood transfusions. His January 2013 conversation with Oprah Winfrey was the first on-camera admission, and the United States Anti-Doping Agency's October 2012 reasoned decision documented the biochemical and testimonial evidence in detail. None of those substances are exotic, each has an FDA-approved indication for specific medical conditions.

Erythropoietin (EPO)

Erythropoietin is a glycoprotein hormone produced by peritubular fibroblasts in the kidney. It stimulates red blood cell production in the bone marrow. The FDA approved epoetin alfa (Epogen, Procrit) in 1989 for anemia associated with chronic kidney disease (CKD), and later for chemotherapy-induced anemia and anemia in HIV patients receiving zidovudine [1].

In athletes, EPO raises hematocrit and VO2 max illegally. In patients with CKD stage 3 to 5, the same mechanism corrects a genuine deficiency: diseased kidneys produce insufficient endogenous EPO, causing symptomatic anemia. A 2006 trial published in the New England Journal of Medicine (N=1,432, the CREATE trial) examined hemoglobin targets in CKD patients receiving epoetin beta and found that normalizing hemoglobin to 13.0 to 15.0 g/dL did not reduce cardiovascular events compared with a target of 10.5 to 11.5 g/dL [2].

Testosterone

Testosterone is an FDA-approved Schedule III controlled substance indicated for male hypogonadism, delayed puberty, and specific metastatic breast cancer cases [3]. The Endocrine Society's 2018 Clinical Practice Guideline defines biochemical hypogonadism as a total testosterone below 300 ng/dL confirmed on two morning fasting samples [4]. A man with that diagnosis, plus symptoms such as low libido, fatigue, or reduced muscle mass, qualifies for testosterone replacement therapy (TRT).

Armstrong has discussed low testosterone in the context of his testicular cancer history. He was diagnosed with stage 3 testicular cancer in 1996. Orchiectomy and chemotherapy are well-documented causes of hypogonadism; a 2014 study in the Journal of Clinical Oncology found that 36% of testicular cancer survivors met criteria for hypogonadism at long-term follow-up [5].

Human Growth Hormone

Recombinant human growth hormone (somatropin) carries FDA approval for adult growth hormone deficiency, short bowel syndrome, and HIV-related wasting [6]. Armstrong's USADA file listed HGH among the compounds his team used. Prescription access requires documented GH deficiency confirmed by stimulation testing, typically an insulin tolerance test or glucagon stimulation test per the 2011 Endocrine Society GH deficiency guidelines [7].

The Pharmacology of EPO: What It Does and Why It Matters Medically

EPO binds the erythropoietin receptor on burst-forming unit-erythroid progenitor cells, triggering JAK2/STAT5 signaling and reducing apoptosis of red cell precursors. The result is a measurable rise in reticulocyte count within 7 to 10 days and a hemoglobin increase within 2 to 4 weeks at standard doses.

Approved Dosing Ranges

For CKD-related anemia, the FDA label for epoetin alfa specifies a starting dose of 50 to 100 IU/kg three times weekly intravenously or subcutaneously, titrated to keep hemoglobin between 10 and 11 g/dL [1]. The label explicitly states clinicians should not target hemoglobin above 11 g/dL in CKD patients because of cardiovascular risk, a finding confirmed by the TREAT trial (N=4,038), published in the New England Journal of Medicine in 2009, which showed darbepoetin alfa targeting normal hemoglobin levels increased stroke risk (hazard ratio 1.92, 95% CI 1.38 to 2.68, P<0.001) [8].

How Athletes Misused EPO vs. Medical Use

Athletic misuse typically targeted hematocrits of 50% to 55%, far above the therapeutic window for anemia patients. The UCI introduced a hematocrit ceiling of 50% for male riders in 1997 as an indirect test. The clinical target for anemia management is hemoglobin of 10 to 11 g/dL, roughly corresponding to a hematocrit of 30% to 33% in a patient who was previously severely anemic. These are very different physiological states.

How a Regular Patient Accesses These Medications

Patients with documented medical need can legally obtain EPO, testosterone, and growth hormone through standard clinical pathways. The process is not complicated, but it requires objective evidence.

Step 1: Establishing a Diagnosis

A clinician orders targeted laboratory work before prescribing any of these compounds.

For anemia workup, the standard panel includes a complete blood count with differential, reticulocyte count, serum iron, ferritin, TIBC, vitamin B12, folate, and a serum erythropoietin level. CKD staging requires serum creatinine and eGFR. The National Kidney Foundation's KDIGO 2012 guidelines recommend evaluating anemia when hemoglobin falls below 13.0 g/dL in adult males or 12.0 g/dL in adult females [9].

For hypogonadism, the Endocrine Society recommends two morning total testosterone measurements drawn between 7 a.m. And 10 a.m., along with LH, FSH, and prolactin to differentiate primary from secondary hypogonadism [4].

For growth hormone deficiency in adults, the Endocrine Society's 2011 guideline recommends at least one GH stimulation test because random GH levels are diagnostically unreliable [7].

Step 2: Prescription and Dispensing

EPO-stimulating agents (ESAs) require a Risk Evaluation and Mitigation Strategy (REMS) program under FDA mandate. The prescribing clinician must enroll in the ESA APPRISE Oncology Program before prescribing for chemotherapy-related anemia [10]. For CKD-related anemia, REMS enrollment is not required but the hemoglobin monitoring schedule outlined in the label applies.

Testosterone products are Schedule III controlled substances. A valid prescription requires an in-person or telehealth evaluation with documented diagnosis. Refills require periodic lab monitoring: total testosterone, hematocrit, PSA, and a lipid panel at minimum. The FDA updated testosterone labeling in 2015 to require a warning about cardiovascular risk and to restrict indication language to classical hypogonadism [3].

Somatropin prescriptions require documentation of GH deficiency from a specialist, typically an endocrinologist. Insurers usually require prior authorization with stimulation test results attached.

Step 3: Monitoring During Therapy

Monitoring is not optional. For ESA therapy in CKD, hemoglobin should be checked every 2 to 4 weeks during dose adjustment and every 1 to 3 months once stable [9]. For TRT, the Endocrine Society recommends checking testosterone levels at 3 months, then annually, along with hematocrit to detect erythrocytosis, a real adverse effect of TRT that mirrors the EPO effect athletes sought deliberately [4].

The table below summarizes the access pathway for each compound class Armstrong is associated with.

| Compound Class | FDA-Approved Indication | Key Diagnostic Threshold | Monitoring Frequency | |---|---|---|---| | Epoetin alfa / ESA | CKD anemia, chemo anemia, HIV/zidovudine anemia | Hgb <10 g/dL (CKD) | Every 2-4 weeks during titration | | Testosterone (TRT) | Male hypogonadism | Total T <300 ng/dL x2 morning draws | Hematocrit and T level at 3 months, then annually | | Somatropin (HGH) | Adult GHD, HIV wasting, short bowel | Failed GH stimulation test | IGF-1 every 6 months | | Cortisone / corticosteroids | Inflammation, autoimmune conditions | Clinical diagnosis | Varies by indication |

Armstrong's Testicular Cancer and the Medical Context

Understanding Armstrong's cancer history matters for clinical context. Stage 3 testicular germ cell tumors with brain metastases, which is what Armstrong had in 1996, carry a treatment protocol involving orchiectomy plus bleomycin, etoposide, and cisplatin (BEP) chemotherapy [11]. Both orchiectomy and platinum-based chemotherapy cause hypogonadism through direct testicular damage and hypothalamic-pituitary axis disruption.

Hypogonadism After Testicular Cancer Treatment

A prospective Norwegian cohort study published in the Journal of Clinical Oncology (N=1,409 testicular cancer survivors) found that 29% of men had testosterone levels below 11 nmol/L (approximately 317 ng/dL) at 11-year follow-up, and Leydig cell dysfunction was strongly associated with the number of cisplatin cycles received [5]. This is a well-characterized, guideline-supported indication for TRT evaluation.

Armstrong has stated publicly, in podcast interviews including his own "The Forward" podcast, that he monitors his hormone levels regularly. Whether he currently uses prescribed TRT is not confirmed in public statements. Any inference that his current use is therapeutic should be labeled as such, his cancer history creates a plausible clinical basis, but clinical confirmation has not been made public.

Chemotherapy-Induced Anemia

BEP chemotherapy suppresses bone marrow, producing anemia in a significant proportion of patients. A Cochrane systematic review on ESAs for chemotherapy-induced anemia (Bohlius et al., 2006, updated 2014) covering 57 trials and 9,353 patients found that ESAs reduced the need for red blood cell transfusions (relative risk 0.65, 95% CI 0.62 to 0.68) [12]. This is the mechanism by which Armstrong's treatment-era EPO use could have originated in a medical context, though USADA's evidence showed use extended well beyond any chemotherapy period.

What the USADA Report Actually Said

The USADA's October 2012 "Reasoned Decision" against Armstrong ran 202 pages and included sworn testimony from 26 witnesses, blood passport data, and financial records. The agency described it as "the most sophisticated, professionalized and successful doping program that sport has ever seen."

The report documented EPO use from at least 1998 through 2005, testosterone use in microdose patches to evade testing, blood transfusions, and HGH. The blood passport data showed hematocrit values and reticulocyte counts inconsistent with natural variation. Armstrong was stripped of all seven Tour de France titles and banned from competitive sport for life [13].

What the Science of Blood Passports Shows

The Athlete Biological Passport (ABP) uses longitudinal hematological profiling to detect indirect markers of doping. A 2013 paper in the British Journal of Sports Medicine analyzing ABP methodology found that the model correctly flagged abnormal hematological profiles with a specificity exceeding 99% when using adaptive Bayesian modeling [14]. This is the same methodology applied retrospectively to Armstrong's samples.

Telehealth Access to Hormone Therapies in 2025

Patients no longer need to visit a hospital endocrinology department to begin the evaluation process for TRT or growth hormone therapy. Telehealth platforms licensed in all 50 states can order lab work, review results, and prescribe testosterone, thyroid medications, and other FDA-approved hormone therapies where appropriate.

The process at a compliant telehealth clinic follows this sequence. A patient completes an intake questionnaire covering symptoms, medical history, and current medications. The clinician orders a baseline lab panel. Results are reviewed in a synchronous or asynchronous video visit. If diagnostic criteria are met, a prescription is sent to a compounding pharmacy or retail pharmacy. Follow-up labs are scheduled at the intervals mandated by the prescribing guidelines.

The DEA's telemedicine rules for Schedule III controlled substances, updated under the COVID-era Ryan Haight Act modifications, require at least one synchronous audio-video visit before a controlled substance can be prescribed remotely [15]. Testosterone is Schedule III, so this requirement applies.

Patients should verify that any telehealth provider orders a full diagnostic panel before prescribing, not just a single testosterone level, and not without LH/FSH to rule out secondary causes. The Endocrine Society's guideline language is direct on this point: "We recommend against making a diagnosis of androgen deficiency in the absence of consistent symptoms and signs" [4].

EPO Access for Patients With Anemia in 2025

EPO-stimulating agents are available through specialty pharmacies with a valid prescription. For patients with CKD-related anemia, the prescribing physician is typically a nephrologist or internist managing CKD. For chemotherapy-related anemia, the oncologist manages ESA prescribing under the REMS program.

Cost and Insurance Coverage

Medicare Part B covers ESAs for CKD-related anemia under the ESRD prospective payment bundle for dialysis patients. For non-dialysis CKD patients, coverage varies by plan. The average wholesale price of epoetin alfa is approximately $20 to $25 per 1,000 IU, and a standard starting dose of 100 IU/kg in a 70 kg patient (7,000 IU three times weekly) costs roughly $420 to $525 per week before discounts [1].

Who Should Not Use ESAs

The FDA label and KDIGO guidelines both state that ESAs should not be initiated in CKD patients when hemoglobin exceeds 10 g/dL, due to increased risk of cardiovascular events, thromboembolic events, and potential tumor promotion in cancer patients [1],[9]. Patients with uncontrolled hypertension are also excluded until blood pressure is controlled.

Clinical Takeaways

Armstrong's doping history offers an unintended pharmacology lesson. The compounds he used, EPO, testosterone, HGH, are real drugs with real indications and real risks. The distinction between misuse and medical use is not about the molecule. It is about diagnosis, dose, and monitoring.

A man with total testosterone of 210 ng/dL, documented fatigue, and a history of orchiectomy has a clear pathway to TRT under Endocrine Society guidelines [4]. A patient with CKD stage 4 and hemoglobin of 9.2 g/dL has a clear pathway to ESA therapy under KDIGO guidelines [9]. A cancer survivor with confirmed GH deficiency on stimulation testing has a clear pathway to somatropin under the 2011 Endocrine Society protocol [7].

The pathway begins with a single lab draw. For testosterone, the Endocrine Society specifies total testosterone measured on two separate mornings between 7 a.m. And 10 a.m., with the sample sent to a laboratory using a validated assay, liquid chromatography-tandem mass spectrometry is the preferred method per the 2018 guideline [4].